BioNTech SE

BioNTech SE

Yahoo Finance • yesterday

Most and least shorted mid- to mega-cap healthcare stocks at the end of October

Short interest data from late October 2026 highlights deeply divided investor sentiment across the healthcare sector. Strong bearish bets remain heavily concentrated in high-volatility biotechnology, equipment, and digital health names, wi... Full story

Yahoo Finance • 10 days ago

BioNTech (BNTX) Expanded Its Oncology Pipeline, Is It Still 25% Below Fair Value?

BioNTech (NasdaqGS:BNTX) just expanded its oncology pipeline by announcing new Phase 2 data for pumitamig plus docetaxel in metastatic non small cell lung cancer, alongside a new Phase 3 collaboration in triple negative breast cancer. Des... Full story

Yahoo Finance • 11 days ago

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

BioNTech SE Pumitamig plus docetaxel demonstrated encouraging responses in squamous and non-squamous non-small cell lung cancer across PD-L1 expression levels with a confirmed objective response rate of 36.7% following progression on or a... Full story

Yahoo Finance • 12 days ago

Moderna’s Cancer-Vaccine Leak Spurred Panic Selling as Wall Street Wanted a Cure

Moderna and Merck’s cancer vaccine reduced the risk of melanoma recurrence or death by 42%, but investors questioned its potential across other cancers. Continue Reading... Full story

Yahoo Finance • 13 days ago

BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer

BioNTech SE BioNTech enters a clinical trial collaboration with Gilead Sciences with the aim of improving outcomes in patients with PD-L1 low or negative triple-negative breast cancer The global Phase 3 ROSETTA Breast-01 trial will evolve... Full story

Yahoo Finance • 19 days ago

Trial Miss Might Change The Case For Investing In BioNTech Stock (BNTX)

BioNTech reported topline Phase 2/3 results from the AHEAD-MERIT trial, where BNT113 plus pembrolizumab did not show a statistically significant progression-free survival benefit versus pembrolizumab alone in HPV16+ head and neck cancer, w... Full story

Yahoo Finance • 22 days ago

US Stock Market Today: S&P 500 Futures Edge Higher As Traders Brace For CPI

The Morning Bull - US Market Morning Update Wednesday, Oct, 14 2026 US stocks are set for a cautious, slightly positive open, with the entire mood hanging on inflation. Investors are weighing hotter year ahead price expectations out of th... Full story

Yahoo Finance • 26 days ago

Moderna stock jumps on planned national cancer vaccine effort

Moderna (MRNA) stock popped 9% on Friday after the New York Times reported new details about an effort to accelerate cancer vaccine development. Investors saw the mRNA biotech company, in particular, as a beneficiary. Other pharmaceutical... Full story

Yahoo Finance • 29 days ago

Novavax, Moderna stocks fall after WHO calls plague risk 'low'

Novavax stock (NVAX) fell on Tuesday after a World Health Organization (WHO) spokesperson told reporters that there was a "low" risk of a plague epidemic, after a 28-year-old woman who worked in a Russian anti-plague laboratory died last w... Full story

Yahoo Finance • last month

Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines

Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been’ just a Covid vaccine company. Continue Reading... Full story

Yahoo Finance • last month

Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up?

Quick Read MRNA has surged 506% in 2026 on a top-line win from the 1,137-patient INTerpath-001 melanoma trial, with full Phase 3 data due October 24. BNTX's 5% gain versus Moderna's 506% confirms the market is betting on intismeran specif... Full story

Yahoo Finance • last month

BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline?

BMO (NYSE: BMO) Capital Markets has been quite bullish about BioNTech SE (NASDAQ: BNTX) this year. However, that's no longer the case. On Sept. 8, 2026, BioNTech's shares dipped after BMO downgraded the biotech stock from an "outperform"... Full story

Yahoo Finance • 2 months ago

Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher

Quick Read Moderna surged 5% to $152.83, extending a stunning 137% one-month run fueled solely by its Phase 2b melanoma vaccine data showing a 49% reduction in recurrence risk. BioNTech edged up just 1% despite running a rival mRNA cancer... Full story

Yahoo Finance • 2 months ago

BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients

BioNTech SE Gotistobart continues to show potential aschemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with squamous non-small cell lung cancer, where median survival with current standard of ca... Full story

Yahoo Finance • 2 months ago

3 things to look out for on Monday

[Wall Street New York City] aluxum/E+ via Getty Images Wall Street’s major averages closed higher on Friday after the latest consumer inflation report came in largely in line with expectations. The blue-chip Dow (DJI [https://seekingalph... Full story

Yahoo Finance • 2 months ago

Catalyst Watch: FOMC blockbuster, Salesforce event, and 24-hour trading talk

[Reciprocal Tariffs] Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDAY - SEPTEMBER 14 * VOLATILIT... Full story

Yahoo Finance • 2 months ago

Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat

Quick Read Moderna surges 8% while cancer-vaccine partner Merck slips 0.3% and peer BioNTech gains just 0.5%, pointing to a Moderna-specific momentum or short-squeeze event. XBI falls 0.1% and SPY rises less than 1%, eliminating both sect... Full story

Yahoo Finance • 2 months ago

Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?

Pfizer PFE stock has risen 8.6% in the past three months as investors have gained confidence in the company's ability to stabilize earnings and offset the continued decline in COVID-19 product sales. A key catalyst has been a solid second-... Full story

Yahoo Finance • 2 months ago

MRNA Stock Soars 143% in a Month: Time to Buy, Hold or Sell?

Moderna MRNA shares have surged 143% in the past month, driven largely by recently announced positive late-stage results for a personalized mRNA-based cancer therapy being developed in partnership with Merck MRK. Oncology Win Highlights M... Full story

Yahoo Finance • 2 months ago

BMO lowers Amgen, BioNTech to Market Perform as risk-reward shifts

Investing.com -- BMO Capital Markets downgraded Amgen and BioNTech to Market Perform from Outperform on Tuesday, citing limited near-term upside and more balanced risk-reward for biopharma companies. BMO analyst Evan Seigerman cut Amgen's... Full story